Inhibiting WNT and NOTCH in renal cancer stem cells and the implications for human patients.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 32066735.
- Also identified by DOI 10.1038/s41467-020-14700-7 and PMC identifier 7026425.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Current treatments for clear cell renal cell cancer (ccRCC) are insufficient because two-thirds of patients with metastases progress within two years. Here we report the identification and characterization of a cancer stem cell (CSC) population in ccRCC. CSCs are quantitatively correlated with tumor aggressiveness and metastasis. Transcriptional profiling and single cell sequencing reveal that these CSCs exhibit an activation of WNT and NOTCH signaling. A significant obstacle to the development of rational treatments has been the discrepancy between model systems and the in vivo situation of patients. To address this, we use CSCs to establish non-adherent sphere cultures, 3D tumor organoids, and xenografts. Treatment with WNT and NOTCH inhibitors blocks the proliferation and self-renewal of CSCs in sphere cultures and organoids, and impairs tumor growth in patient-derived xenografts in mice. These findings suggest that our approach is a promising route towards the development of personalized treatments for individual patients.
Medical subject headings
- Antineoplastic Agents
- Carcinoma, Renal Cell
- Kidney Neoplasms
- Neoplastic Stem Cells
- Receptors, Notch
- Wnt Proteins